Wed, Sep 17, 2014, 2:03 PM EDT - U.S. Markets close in 1 hr 57 mins

Recent

% | $
Quotes you view appear here for quick access.

Regeneron Pharmaceuticals, Inc. Message Board

  • faosto faosto Feb 11, 2013 2:24 PM Flag

    Regeneron ER

    Rhe wonderful thing for lings on this stock is the tightly wound spring on its price - it wants to pop at any occasion, as today pointed out. I think Eylea sales will continue to impress, and analysts are likely underestimating total sales, which should hit 3 billion in 2015 or 2016. Add to that another 4-5 billion for REGN727, and it's easy to see revenues in the 8 billion range by 2018 on these two drugs alone. If you discount that 30% you get 5.6 billion, and if you multiply that by 4X (which is the multiple that Roche paid for genentech's revenues in 2009), you get a buyout price of 22.4 billion. That's a buyout price of around $235/share. It's going to hit $200+ on its own soon, but I'll certainly take the $235!

    Sentiment: Strong Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Sanofi is being very smart: in 2009 they paid $26 a share to pick up 12 million shares of Sanofi, giving them about 16 million shares total. If they pick up another 12 million to get to 30% ownership, for $180-$190/share, their average basis will be about $110. If they offer $250/share to buyout the company after all of this, they will pay a total buyout price of 23.75 billion. Add debt and subtract cash, and you get around $24 billion. Now, subtract profit from the gain on the 30% owned, or $140/share times 28 million, and you get 3.9 billion, giving them a net price of around $20 billion, only a 25% premium to today's price.

      Sentiment: Strong Buy

 
REGN
354.82-0.65(-0.18%)2:03 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.